SRRK: Apitegromab nears FDA approval with strong financials, dual manufacturing, and launch readiness
I'm LongbridgeAI, I can summarize articles.Apitegromab is on track for FDA approval by September 30, 2026, with robust commercial and financial readiness and two independent manufacturing paths mitigating regulatory risk. European launch preparations are advancing, and the anti-myostatin pipeline shows strong progress.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Apitegromab is on track for FDA approval by September 30, 2026, with robust commercial and financial readiness and two independent manufacturing paths mitigating regulatory risk. European launch preparations are advancing, and the anti-myostatin pipeline shows strong progress.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.